Nocturnal polyuria or nocturia is a condition that causes you to wake up during the night to urinate or increased frequency of having to urinate more often at night. It is important to distinguish nocturia (urinating too frequently) from polyuria (urinating too much volume). This condition becomes more common as people age and occurs in both men and women. It can be common for most people to wake up once during the night to urinate, but urinating more recurrently can be associated with daytime urinary frequency or the condition can occur by itself. Treatment of nocturia includes certain activities, such as restricting fluids and medications that reduce symptoms of overactive bladder
COVID-19 scenario analysis:
Pharmaceutical and biotechnological companies together with governments around the globe are working to combat the COVID-19 outbreak, from supporting the development of vaccines to scheduling medicines supply chain challenges. Around 115 vaccine candidates and other 155 molecules are in the R&D pipeline. Furthermore, the commonly used drugs, such as hydroxychloroquine, have observed huge boost in demand for the management of COVID-19. In addition, increase has been experienced in the demand for COVID-19 management drugs, which is expected to offer potential opportunity for manufacturers of drugs, as many developed countries are short of these drugs. Owing to the growing demand for vaccine and treatment drugs for COVID-19, the pharmaceutical and biotechnology industry is anticipated to witness a substantial growth in the next few years.
Top impacting factors: market scenario analysis, trends, drivers, and impact analysis
The major factor affecting the market include surge in geriatric population. In addition, increase in the prevalence of organ failure would help the market gain traction in the next few years. Furthermore, rise in cases of high salt intake and hypertension is expected to help the market gain momentum in the coming years. Improvement in the healthcare infrastructure in the current years and the development observed in the diagnostics segment would help the market flourish. However, COVID-19 impact may hinder the growth of the market.
Increase in the number of product launches
Increase in the number of product launches would help the market flourish during the forecast period. For instance, in March 2017, the U.S. Food and Drug Administration approved Noctiva (desmopressin acetate) nasal spray for adults who are awaken at least two times per night to urinate due to a condition known as nocturnal polyuria (overproduction of urine during the night). In May 2018, Avadel Pharmaceuticals Plc. announced the launch of Noctiva (desmopressin acetate), an emulsified microdose Nasal Spray. Noctiva is the first and only FDA-approved treatment proven to help adults with nocturia due to nocturnal polyuria, a condition which causes the kidneys to overproduce urine at night. Noctiva safely and effectively treats a condition that causes more than 40 million Americans to wake two or more times per night to use the bathroom and prevents them from getting a good night’s sleep.
Surge in prevalence of nocturia
Increase in prevalence of nocturia is anticipated to help the market boost in the coming years. According to the International Continence Society (ICS), around 45% of men aged 50–59 year, 60% of those aged 60–69 year, and around 75% in their seventies are affected. If a more restrictive definition of nocturia is considered (two or more voids per night), the figures drop to 10%, 20%, and 30%, respectively. Although the consensual ICS definition sticks to the cut-off of one void per night, many others argue that choosing two voids per night might be more clinically relevant and better correlated to quality of life (QoL) impairment.
Key benefits of the report:
- This study presents the analytical depiction of the global nocturnal polyuria treatment industry along with the current trends and future estimations to determine the imminent investment pockets.
- The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the global nocturnal polyuria treatment market share.
- The current market is quantitatively analyzed to highlight the global nocturnal polyuria treatment market growth scenario.
- Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
- The report provides a detailed global nocturnal polyuria treatment market analysis based on competitive intensity and how the competition will take shape in coming years.
Questions answered in the nocturnal polyuria treatment market research report:
- Which are the leading players active in the nocturnal polyuria treatment market?
- What are the current trends that will influence the market in the next few years?
- What are the driving factors, restraints, and opportunities of the market?
- What are the projections for the future that would help in tasking further strategic steps?
Nocturnal Polyuria Treatment Market Report Highlights
| Aspects | Details |
 By Type |
|
 By Distribution Channel |
|
 By Region |
|
 Key Market Players | Avadel Pharmaceuticals,, Allergan, Inc.,, Glenmark Pharmaceuticals Limited,, Astellas Pharma Inc.,, Nexus Pharma Co., Ltd, Ferring Holding SA,, Urigen Pharmaceuticals, Inc.,, Vantia Therapeutics,, AA Pharma Inc.,, Teva Pharmaceutical Industries Ltd, |
Loading Table Of Content...
